evelo-logo.png
Evelo Biosciences Reports Second Quarter 2018 Financial Results and Recent Business Highlights
August 02, 2018 08:00 ET | Evelo Biosciences, Inc.
-- Advancing Multiple Product Candidates into Clinical Trials with Dosing of First Patient in Phase 1 Trial of EDP1066 in Psoriasis and Atopic Dermatitis and FDA Acceptance of IND for Phase 2a...
evelo-logo.png
Evelo Biosciences Added To Russell 3000®, 2000® and Microcap® Indexes
June 25, 2018 08:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company pioneering monoclonal microbials designed to act on the gut-body...
evelo-logo.png
Evelo Biosciences to Present at the JMP Securities 2018 Life Sciences Conference
June 14, 2018 08:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., June 14, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company pioneering monoclonal microbials designed to act on the gut-body...
evelo-logo.png
Evelo Biosciences Reports First Quarter 2018 Financial Results and Recent Business Highlights
May 31, 2018 08:00 ET | Evelo Biosciences, Inc.
-- Dosing Underway in Phase 1 Clinical Trial of EDP1066 in Psoriasis and Atopic Dermatitis -- -- IND Accepted by FDA for Phase 2a Investigator-Sponsored Clinical Trial of EDP1503 in Metastatic...
evelo-logo.png
Evelo Biosciences Announces Closing of Initial Public Offering
May 11, 2018 17:00 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., May 11, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo”) today announced the closing of its initial public offering of 5,312,500 shares of common stock at a...
Evelo Biosciences Announces Pricing of Initial Public Offering
May 08, 2018 19:29 ET | Evelo Biosciences, Inc.
CAMBRIDGE, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo”) today announced the pricing of its initial public offering of 5,312,500 shares of common stock at a...